UK's AMRC Licenses Shionogi Superbug Therapy
As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.
You may also be interested in...
Using live bacteria modified to deliver specific proteins to treat cancer is to be explored by the Swiss start-up, T3 Pharmaceuticals, which has garnered a large third round of funding from a European corporate VC, institutional and private investors, to advance its lead candidate into clinical trials.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
The Swiss group's one-dose drug, seen as a future growth driver, is as effective as its off-patent blockbuster Tamiflu in treating children.